Insulin-Like Growth Factor I (IGF1)
Insulin-like growth factor 1 (IGF-1), also known as somatomedin C, is a small polypeptide hormone similar to proinsulin, an insulin progenitor. IGF-1 is produced mainly by the liver; however, some peripheral tissues produce IGF-1 in response to growth hormone (GH). The main function of IGF-1 is to mediate the growth-promoting effects of human GH in peripheral tissues. Its action is insulin-like, especially in fat and muscle. In addition, it also stimulates collagen and protein synthesis. IGF-1 circulates in the body mostly bound to insulin-like growth factor binding proteins (IGFBP). Concentration of IGF-1 is regulated by genetic factors, nutrient intake, GH, Insulin-like growth factor binding proteins, insulin, T4, cortisol, sex hormones and age.
Testing for IGF-1 is used for evaluation of growth activity, the responsiveness of peripheral tissues to changes in GH secretion, and for the diagnosis of related disorders. Since blood levels of IGF-1 are stable through the day, IGF-1 is a sensitive test for acromegaly. Acromegaly is a disorder that results when the pituitary gland produces excess growth hormone. Both IGF-1 and GH are increased in acromegaly. Normal IGF-1 levels rule out active acromegaly. Values may be normal, however, in GH-deficient patients with hyperprolactinemia or craniopharyngioma. This test is also used to evaluate hypopituitarism and hypothalamic lesions in children. IGF-1 is also very useful in monitoring GH treatment.
Low levels of IGF-1 are seen in malnutrition, pituitary dwarfism (short statue), hypopituitarism, Laron-type dwarfism (usually due to tissue resistance to GH), hypothyroidism, and cirrhosis of the liver.
- Diagnosis of acromegaly
- Growth hormone therapy treatment monitoring
- As an aid in diagnosis of dwarfism
Increased in:
- Acromegaly
- GH treatment (such as in Laron-type dwarfism)
- Some cancers
Decreased in:
- Pituitary dwarfism
- Hypopituitarism
- Laron-type dwarfism (resistance to GH)
- Malnutrition
- Hypothyroidism
- Liver cirrhosis
| Age / Sex | ng/mL or mg/L |
| 1–2 yr Male | 31–160 |
| 1–2 yr Female | 11–206 |
| 3–6 yr Male | 16–288 |
| 3–6 yr Female | 70–316 |
| 7–10 yr Male | 136–385 |
| 7–10 yr Female | 123–396 |
| 11–12 yr Male | 136–440 |
| 11–12 yr Female | 191–462 |
| 13–14 yr Male | 165–616 |
| 13–14 yr Female | 286–660 |
| 15–18 yr Male | 134–836 |
| 15–18 yr Female | 152–660 |
| 19–25 yr Male | 202–433 |
| 19–25 yr Female | 231–550 |
| Adult 26–85 yr | 135–449 |
Electrochemiluminescence immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum (Red) or Plasma EDTA (Lavender),Heparin (Green).
Separate serum or Plasma and keep frozen.
SST is not acceptable. Freeze immediately.
Stability
- Ambient: 48 hours
- Refrigerated: 5 days
- Frozen: 30 days
- Eur J Obstet Gynecol Reprod Biol. 2011 Nov 8. [PMID: 22071113]
- Minerva Endocrinol. 2004;29:207. [PMID: 15765030]
- Nat Clin Pract Endocrinol Metab. 2006;2:436. [PMID: 16932333]
- N Engl J Med. 2006;355:2558. [PMID: 17167139]
- Nat Clin Pract Endocrinol Metab. 2006;2:436. [PMID: 16932333]